Agile Therapeutics, Inc (AGRX) Q4 2022 Earnings Conference Call March 22, 2023 4:30 PM ET
Company Participants
Matt Riley - Head, Investor Relations
Al Altomari - Chairman and Chief Executive Officer
Amy Welsh - Chief Commercial Officer
Jason Butch - Chief Accounting Officer
Conference Call Participants
Oren Livnat - H.C. Wainwright
Operator
Good afternoon and welcome to the Agile Therapeutics Fourth Quarter and Full Year 2022 Financial Results Conference Call. Please note, today’s event is being recorded. I would now like to turn the conference over to Matt Riley, Head of Investor Relations.
Matt Riley
Hello, everyone and welcome to today’s conference call to discuss our fourth quarter and full year 2022 financial results and corporate update. Before we start, let me remind you that today’s call will include forward-looking statements based on our current expectations, including statements concerning our financial outlook and financing prospects for the future; our outlook for the first half and full year of 2023; management’s expectations for our future financial and operational performance, including our expectations regarding the market growth of Twirla and our operating expenses; our business strategy; our partnership with Afaxys and its ability to promote growth; our product supply agreement with Nurx and its ability to make Twirla broadly in hub locations; our digital advertising campaign and its ability to promote growth; and our assessment of the combined hormonal contraceptive market generally, among other statements concerning our plans, prospects and expectations. Such statements represent our judgments as of today, are not promises or guarantees and may involve risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements.
Further, during the course of today’s call, we will refer to certain non-GAAP financial measures. A reconciliation of GAAP to non-GAAP measures is included in our press release issued today, which
- Read more current AGRX analysis and news
- View all earnings call transcripts